4.
In the control group, six of 100 people with moderate to severe, or severe, asthma had at least one serious adverse event over a 16‐ to 60‐week period compared with five (95% CI 4 to 6) of 100 for the omalizumab group.
Official websites use .gov
A
.gov website belongs to an official
government organization in the United States.
Secure .gov websites use HTTPS
A lock (
) or https:// means you've safely
connected to the .gov website. Share sensitive
information only on official, secure websites.